26th Annual Acute Leukemia Forum

SAVE THE DATE | LA JOLLA, CALIFORNIA

May 5, 2022 – May 6, 2022

Hybrid

swoosh
swoosh

ACCREDITATION STATEMENT

[JALOGO] In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

[bold]Physician Continuing Medical Education[/bold] The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 10.0 [italic]AMA PRA Category 1 Credits™[/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]Continuing Nursing Education[/bold] The maximum number of hours awarded for this Continuing Nursing Education activity is 10.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined. [bold]Continuing Pharmacy Education[/bold] Postgraduate Institute for Medicine designates this continuing education activity for 10.0 contact hour(s) (0.010 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-22-622-L04-P Type of Activity: Knowledge [bold]Policy on Privacy and Confidentiality:[/bold] Please see final activity for the policy on privacy and confidentiality that relates to this internet activity. [bold]Disclosure of Unlabeled Use[/bold] This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. [bold]Disclaimer[/bold] Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Learning Objectives

Upon completion of this activity, participants will: [LIST] [ITEM]Evaluate updates in the treatment and management of myelodysplasia [ITEM]Appraise the clinical potential of novel strategies in the management of various subsets of ALL [ITEM]Assess recent advances in the biology and treatment of AML [ITEM]Recognize critical updates in bone marrow transplantation and management of GVHD [ITEM]Apply evidence based strategies to integrate progress into clinical practice [/LIST]